RAPT Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
70
- Stock Symbol
-
RAPT
- Share Price
-
$1.19
- (As of Thursday Closing)
RAPT Therapeutics General Information
Description
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Contact Information
Website
www.rapt.comCorporate Office
- 561 Eccles Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 561 Eccles Avenue
- South San Francisco, CA 94080
- United States
RAPT Therapeutics Stock Performance
As of 23-Jan-2025, RAPT Therapeutics’s stock price is $1.19. Its current market cap is $157M with 132M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.19 | $1.22 | $0.79 - $27.35 | $157M | 132M | 3.56M | -$2.78 |
RAPT Therapeutics Financials Summary
As of 30-Sep-2024, RAPT Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (38,955) | 677,431 | 484,936 | 874,441 |
| Revenue | 0 | 0 | 1,527 | 3,813 |
| EBITDA | (106,253) | (115,582) | (82,791) | (68,208) |
| Net Income | (107,492) | (116,798) | (83,838) | (69,204) |
| Total Assets | 108,465 | 173,329 | 266,209 | 198,636 |
| Total Debt | 5,120 | 6,906 | 8,990 | 0 |
RAPT Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
RAPT Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
RAPT Therapeutics Comparisons
Industry
Financing
Details
RAPT Therapeutics Competitors (60)
One of RAPT Therapeutics’s 60 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnaptysBio | Formerly VC-backed | San Diego, CA | ||||
| CalciMedica | Formerly VC-backed | San Diego, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA |
RAPT Therapeutics Patents
RAPT Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230322741-A1 | Chemokine receptor modulators and uses thereof | Pending | 06-Apr-2022 | ||
| AU-2023248361-A1 | Chemokine receptor modulators and uses thereof | Pending | 06-Apr-2022 | ||
| US-20220305018-A1 | Pyrazole pyrimidine compounds and uses thereof | Active | 15-Mar-2021 | ||
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | Active | 15-Mar-2021 | ||
| US-20220251070-A1 | Methods of making trans isomeric forms of g protein-coupled receptor modulators | Pending | 02-Feb-2021 | C07D401/14 |
RAPT Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
RAPT Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2023
26.61 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
RAPT Therapeutics FAQs
-
When was RAPT Therapeutics founded?
RAPT Therapeutics was founded in 2015.
-
Where is RAPT Therapeutics headquartered?
RAPT Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of RAPT Therapeutics?
RAPT Therapeutics has 70 total employees.
-
What industry is RAPT Therapeutics in?
RAPT Therapeutics’s primary industry is Drug Discovery.
-
Is RAPT Therapeutics a private or public company?
RAPT Therapeutics is a Public company.
-
What is RAPT Therapeutics’s stock symbol?
The ticker symbol for RAPT Therapeutics is RAPT.
-
What is the current stock price of RAPT Therapeutics?
As of 23-Jan-2025 the stock price of RAPT Therapeutics is $1.19.
-
What is the current market cap of RAPT Therapeutics?
The current market capitalization of RAPT Therapeutics is $157M.
-
Who are RAPT Therapeutics’s competitors?
AnaptysBio, CalciMedica, Kite Pharma, NexImmune, and Marengo Therapeutics are some of the 60 competitors of RAPT Therapeutics.
-
What is RAPT Therapeutics’s annual earnings per share (EPS)?
RAPT Therapeutics’s EPS for 12 months was -$2.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
